<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30226" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tizanidine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ghanavatian</surname>
            <given-names>Shirin</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Derian</surname>
            <given-names>Armen</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shirin Ghanavatian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Armen Derian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30226.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tizanidine is an FDA-approved drug for managing spasticity. It is a centrally acting alpha-2 receptor agonist. Tizanidine effectively works with spasticity caused by multiple sclerosis, an acquired brain injury, or a spinal cord injury. It has also been shown to be clinically effective in managing patients suffering from chronic neck and lumbosacral neuralgia with a myofascial component to their pain and regional musculoskeletal pain syndromes. It is also prescribed off-label for migraine headaches, insomnia, and as an anticonvulsant. Tizanidine can also be applied as part of a detoxification therapy regimen in patients exhibiting analgesic rebound headaches to assist with analgesic withdrawal. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, toxicity, and monitoring, of tizanidine so providers can direct patient therapy as part of the inter-professional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of tizanidine.</p></list-item><list-item><p>Identify the clinical indications for tizanidine use.</p></list-item><list-item><p>Review the adverse reaction profile of tizanidine.</p></list-item><list-item><p>Summarize inter-professional team strategies for improving care, coordination, and communication for improving patient outcomes related to tizanidine therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30226&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30226">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30226.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tizanidine is a&#x000a0;centrally acting alpha-2 agonist. Tizanidine is&#x000a0;widely used as an&#x000a0;anti-spastic agent for multiple medical conditions.</p>
        <p>
<bold>FDA-approved Indication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tizanidine is indicated&#x000a0;for spasticity management due to&#x000a0;multiple sclerosis, spinal cord injury, stroke, amyotrophic lateral sclerosis, and traumatic brain injury.<xref ref-type="bibr" rid="article-30226.r1">[1]</xref><xref ref-type="bibr" rid="article-30226.r2">[2]</xref><xref ref-type="bibr" rid="article-30226.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic neck and lower back pain<xref ref-type="bibr" rid="article-30226.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Rebound headaches due to analgesic withdrawal<xref ref-type="bibr" rid="article-30226.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic migraine headaches<xref ref-type="bibr" rid="article-30226.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Refractory&#x000a0;insomnia in spastic quadriplegic patients<xref ref-type="bibr" rid="article-30226.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Regional musculoskeletal pain syndromes<xref ref-type="bibr" rid="article-30226.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Clinical Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Placebo-controlled studies confirm the significant efficacy of tizanidine in reducing&#x000a0;spasticity in patients with spinal cord-induced spasticity. Literature suggests that patients with severe spasticity are more likely to benefit from the therapy. Drug comparison studies have shown no differences in the efficacy of tizanidine compared with baclofen or diazepam. The tizanidine treatment group did not report increased weakness compared to the controls. Furthermore, patients&#x000a0;given&#x000a0;tizanidine&#x000a0;experienced fewer adverse effects than those using controlled substances.<xref ref-type="bibr" rid="article-30226.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Studies&#x000a0;exhibit that tizanidine, baclofen, and diazepam effectively decreased excessive muscle tone in patients with multiple sclerosis or cerebrovascular lesions. Muscle strength improved in all three treatment groups, but the improvement was most significant with&#x000a0;tizanidine. Shakespeare et al. also reported similar findings showing no differences in efficacy between tizanidine, baclofen, and dantrolene compared to diazepam. However, diazepam was associated with more sedation.<xref ref-type="bibr" rid="article-30226.r9">[9]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Another study by Lataste et al.&#x000a0;showed no significant differences between tizanidine and baclofen or diazepam for muscle tone, muscle spasms, clonus, muscle strength, or overall anti-spastic effect. However, tizanidine tolerance is slightly better than diazepam and baclofen.<xref ref-type="bibr" rid="article-30226.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Groves et al. report no significant differences between tizanidine, baclofen, or diazepam for spasticity by Ashworth score. However, applying global tolerability to treatment favored tizanidine compared to baclofen and diazepam.<xref ref-type="bibr" rid="article-30226.r11">[11]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Animal studies have shown that tizanidine provides benefits in the perioperative period and the management of neuropathic pain, such as trigeminal neuralgia, similar to the effects of clonidine under similar circumstances.</p>
          </list-item>
          <list-item>
            <p>A recent study indicates that tizanidine and other alpha-2 agonists can be used&#x000a0;for medically supervised opioid withdrawal.<xref ref-type="bibr" rid="article-30226.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>The American Academy of Neurology guidelines reports that tizanidine should be used for generalized spasticity in cerebral palsy,&#x000a0;for segmental/localized spasticity treatment with botulinum toxin-A is more effective.<xref ref-type="bibr" rid="article-30226.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30226.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist. Tizanidine inhibits&#x000a0;the release of excitatory amino acids like glutamate and aspartate from spinal interneurons. Consequently, tizanidine enhances the presynaptic inhibition of motor neurons. Tizanidine has&#x000a0;significant&#x000a0;action on spinal polysynaptic pathways.<xref ref-type="bibr" rid="article-30226.r14">[14]</xref></p>
        <p>The overall effect of these actions is to reduce the facilitation of spinal motor neurons. Similarly, alpha-2 receptor-mediated inhibition of inter-neuronal activity appears to underlie tizanidine's additional anti-nociceptive and anti-convulsant activities. Spasm frequency and clonus are also reduced by&#x000a0;tizanidine.<xref ref-type="bibr" rid="article-30226.r15">[15]</xref></p>
        <p>Tizanidine&#x000a0;also&#x000a0;has an affinity for the alpha-1 receptors but to a lesser degree, which may explain its mild and transitory effect on the cardiovascular system compared to clonidine despite their structural and biochemical similarity.<xref ref-type="bibr" rid="article-30226.r16">[16]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;&#x000a0;</bold>
</p>
        <p>Absorption: Tizanidine has a significant, first-pass hepatic metabolism with an oral bioavailability of 20% to 34%. Tizanidine attains the steady-state concentration within 24 to 48 hours after administration. There is no noticeable change in its pharmacokinetic&#x000a0;behavior with repeated intake.<xref ref-type="bibr" rid="article-30226.r17">[17]</xref></p>
        <p>Distribution: Tizanidine has extensive tissue distribution; the volume of distribution is 2.4 L/kg. The plasma protein binding of tizanidine is approximately 30%.</p>
        <p>Metabolism:&#x000a0;Tizanidine is metabolized extensively in the liver by cytochrome P450-1A2 to inactive metabolites.</p>
        <p>Excretion:&#x000a0;Tizanidine has an elimination half-life of 2.5 hours, follows linear pharmacokinetics,&#x000a0;and is excreted 60% through urine and 20% through feces.<xref ref-type="bibr" rid="article-30226.r18">[18]</xref></p>
      </sec>
      <sec id="article-30226.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Tizanidine is administrated orally as&#x000a0;2 mg, 4 mg, and 6 mg&#x000a0;capsules or as&#x000a0;2 mg&#x000a0;and&#x000a0;4 mg&#x000a0;tablets. Dosage starts with 2 mg orally&#x000a0;and may repeat every 6 to 8 hours as needed. The dosage may gradually increase by 2 to 4 mg per dose for 1 to 4 days in between until there is a noticeably significant reduction of spasticity. Maximum dosing is three doses every 24 hours, up to 36 mg daily.</p>
        <p>If tizanidine is&#x000a0;used for more than nine weeks or given in high doses ranging from 20 mg to 36 mg daily, taper the dose gradually. The recommendation&#x000a0;is to taper the dose to 2 to 4 mg daily to&#x000a0;reduce the risk of tachycardia, rebound hypertension, and increased spasticity.<xref ref-type="bibr" rid="article-30226.r19">[19]</xref></p>
        <p>The patient may open the capsule and sprinkle the contents into food. Patients can take tizanidine with food or on an empty stomach. It is important to note that&#x000a0;the&#x000a0;extent of absorption is&#x000a0;greater when taken with food.&#x000a0;The tablet and capsule dosage forms are not bioequivalent when administered with food. Hence, the clinician should counsel the patient to take tizanidine with or without food but&#x000a0;be consistent to avoid fluctuations in concentration.<xref ref-type="bibr" rid="article-30226.r20">[20]</xref>&#x000a0;It is also important to recognize that smoking decreases tizanidine's plasma concentration and exposure(AUC).<xref ref-type="bibr" rid="article-30226.r21">[21]</xref></p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p><bold>Patients with Hepatic Impairment: </bold>The consequence of Hepatic impairment on the pharmacokinetics of tizanidine has not been evaluated. However, tizanidine is extensively metabolized by the liver; therefore, hepatic impairment would significantly influence the pharmacokinetics of tizanidine. Therefore, tizanidine should be avoided or used with extreme caution in patients with hepatic impairment.</p>
        <p><bold>Patients with Renal Impairment: </bold>Tizanidine should be used cautiously in patients with renal impairment (creatinine clearance &#x0003c; 25 mL/min), as clearance is decreased by more than 50%. Start with a low dose, evaluate the response to therapy, and if a higher dose is needed, the dose can be increased rather than increasing the frequency of administration. The clinician should monitor the patient closely for adverse drug reactions such as dry mouth, drowsiness, asthenia, and dizziness as indicators of toxicity.</p>
        <p><bold>Pregnancy Considerations: </bold>The use of tizanidine in managing spinal cord injury during pregnancy has been described in case reports.<xref ref-type="bibr" rid="article-30226.r22">[22]</xref> However, it is important to note that tizanidine is a former FDA pregnancy category-C and should be used only if indicated after careful risk-benefit evaluation.</p>
        <p><bold>Breastfeeding Considerations: </bold>Tizanidine is a lipid-soluble drug; hypothetically, it may be present in&#x000a0;breast milk; its use during lactation is not advised.</p>
      </sec>
      <sec id="article-30226.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Tizanidine is generally well-tolerated. However, reports exist of potential adverse effects on several organs, such as cutaneous, gastrointestinal, neurologic, cardiovascular, endocrine, and respiratory systems.</p>
        <p>
<bold>Common Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
          <list-item>
            <p>Asthenia</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Dyskinesia</p>
          </list-item>
          <list-item>
            <p>Nervousness</p>
          </list-item>
          <list-item>
            <p>Hallucination</p>
          </list-item>
          <list-item>
            <p>Rhinitis</p>
          </list-item>
          <list-item>
            <p>Xerostomia<xref ref-type="bibr" rid="article-30226.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Dizziness<xref ref-type="bibr" rid="article-30226.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Severe Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe hepatotoxicity and liver failure<xref ref-type="bibr" rid="article-30226.r24">[24]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Exfoliative dermatitis</p>
          </list-item>
          <list-item>
            <p>Severe hypotension<xref ref-type="bibr" rid="article-30226.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>QT interval prolongation<xref ref-type="bibr" rid="article-30226.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Severe bradycardia<xref ref-type="bibr" rid="article-30226.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome<xref ref-type="bibr" rid="article-30226.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Refractory hypokalemia and potassium wasting nephropathy<xref ref-type="bibr" rid="article-30226.r29">[29]</xref></p>
          </list-item>
        </list>
        <p><bold>Withdrawal Symptoms</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Rebound hypertension</p>
          </list-item>
          <list-item>
            <p>Increased spasticity&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Withdrawal symptoms are more likely to occur when discontinuing the drug abruptly.<xref ref-type="bibr" rid="article-30226.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Concomitant use of tizanidine with fluvoxamine or ciprofloxacin is contraindicated due to significant hypotension and increased psychomotor impairment.<xref ref-type="bibr" rid="article-30226.r30">[30]</xref>&#x000a0;A recent retrospective analysis of the WHO pharmacovigilance database identified severe cardiac and nervous system adverse drug reactions. The study concluded that the concomitant use of ciprofloxacin with tizanidine should be avoided.<xref ref-type="bibr" rid="article-30226.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Because of potential drug interactions, using tizanidine with other CYP1A2 inhibitors such as oral contraceptives containing Ethinyl estradiol and gestodene, dronedarone, pimozide, saquinavir, cimetidine, famotidine, acyclovir,&#x000a0;and ticlopidine should be avoided due to decreased clearance of tizanidine.<xref ref-type="bibr" rid="article-30226.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>If tizanidine is clinically necessary, therapy should be initiated with 2 mg and increased to 2 to 4 mg daily based on patient response to therapy.</p>
          </list-item>
          <list-item>
            <p>Adverse reactions such as hypotension, bradycardia, or excessive sedation require gradual dose reduction or stopping therapy.</p>
          </list-item>
          <list-item>
            <p>Tizanidine should be used cautiously in patients on other alpha-2 adrenergic receptor agonists.</p>
          </list-item>
          <list-item>
            <p>Patients should avoid alcohol and benzodiazepines with tizanidine as it&#x000a0;can lead to excessive sedation and myocardial toxicity in rare instances.<xref ref-type="bibr" rid="article-30226.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Vemurafenib used in&#x000a0;BRAF&#x000a0;mutation-positive malignancy is an inhibitor of CYP1A2 and can increase&#x000a0;plasma concentration of tizanidine,&#x000a0;leading to&#x000a0;potential toxicity.<xref ref-type="bibr" rid="article-30226.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30226.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to tizanidine or its ingredients is a contraindication to the use of tizanidine.</p>
          </list-item>
          <list-item>
            <p>Tizanidine use requires caution in patients with hepatic impairment. Review articles on tizanidine report cases of severe hepatotoxicity, acute liver failure, and death.<xref ref-type="bibr" rid="article-30226.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>According to product labeling, tizanidine use requires caution in patients with renal impairment (creatinine clearance &#x0003c; 25 mL/min). In such patients, decrease the dose. If high doses are necessary, increase the individual dosage rather than the dosage frequency.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30226.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine and liver function tests require measurement at baseline, then one month after the maintenance dose is achieved. Periodically monitor liver function tests in patients managed with tizanidine chronically and in higher doses.<xref ref-type="bibr" rid="article-30226.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Monitor blood pressure and heart rate before increasing the&#x000a0;dosage because of the risk of severe hypotension associated with the higher dose.<xref ref-type="bibr" rid="article-30226.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Monitor the level of spasticity by&#x000a0;Ashworth and modified Ashworth Scales.<xref ref-type="bibr" rid="article-30226.r35">[35]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with multiple sclerosis, monitor spasticity using MS Spasticity Scale(MSSS-88).<xref ref-type="bibr" rid="article-30226.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30226.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>The maximum recommended dose of tizanidine is 36 mg/day.<xref ref-type="bibr" rid="article-30226.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>In the retrospective review, which included 45 patients, the mean dose ingested&#x000a0;was&#x000a0;72 mg (Above the maximum recommended dose).</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lethargy</p>
          </list-item>
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Agitation</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>There is no antidote for tizanidine toxicity.</p>
          </list-item>
          <list-item>
            <p>Tizanidine overdose management is by close monitoring of airways, administration of intravenous fluid, and&#x000a0;vasopressors as necessary.<xref ref-type="bibr" rid="article-30226.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>The pediatric case report described an overdose of tizanidine in spastic quadriplegia and toxicity presented with&#x000a0;multiple organ dysfunction&#x000a0;in the absence of&#x000a0;sepsis.<xref ref-type="bibr" rid="article-30226.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>A recent case report described the altered mental status and hemodynamic instability&#x000a0;due to tizanidine overdose, and naloxone 10 mg IV administration improved Richmond Agitation-Sedation Scale(RASS).<xref ref-type="bibr" rid="article-30226.r38">[38]</xref> The study concluded that naloxone could be used in tizanidine overdose in emergency settings; however,&#x000a0;naloxone&#x000a0;does not reverse the hemodynamic parameters.<xref ref-type="bibr" rid="article-30226.r39">[39]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30226.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tizanidine is a centrally acting alpha-2 agonist prescribed to manage spasticity caused by multiple sclerosis, stroke, and spinal cord injury. Tizanidine is also used off-label for managing patients suffering from chronic neck and back pain and chronic migraines.&#x000a0;However, this drug can cause hypotension, bradycardia, and hepatotoxicity. Hence all healthcare providers need to understand indications, mechanisms, adverse effects, and their management.&#x000a0;</p>
        <p>The clinician prescribes tizanidine for appropriate indication and&#x000a0;should assess liver function tests at baseline and one month. In addition, the neurologist should evaluate the improvement in spasticity related to neurological disorders such as multiple sclerosis, stroke, and spinal cord injury. Nurses can check compliance, monitor for adverse events, and counsel patients for adherence to therapy. The pharmacist should verify the dosing regimen, perform medication reconciliation for drug interactions, and counsel the patient on adverse drug reactions. In addition, patients need to be warned not to combine it with antihypertensive medications. In the overdose of tizanidine, triage nurses should admit the patient, and the emergency department physicians should monitor blood pressure and heart rate and obtain 12 lead EKG. Additionally, a liver function test is required to assess for hepatotoxicity. The critical care physician should manage severe overdose, which requires vasopressors and fluids during the ICU stay.</p>
        <p>As depicted above, there are multiple healthcare providers, including clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, and nurses, involved in taking care of the patient. Tizanidine can be an effective therapeutic agent, but it requires the entire interprofessional healthcare team to collaborate and communicate for therapy to be successful.&#x000a0;In addition, a recent study noted that interprofessional care between clinicians, neurologists, pharmacists, nurses, physical therapists,&#x000a0;speech and language therapists, and occupational therapists is crucial for providing patient-centered care in patients with multiple sclerosis.<xref ref-type="bibr" rid="article-30226.r40">[40]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-30226.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30226&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30226">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30226/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30226">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30226.s11">
        <title>References</title>
        <ref id="article-30226.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henney</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Runyan</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>425</fpage>
            <page-range>425-39</page-range>
            <pub-id pub-id-type="pmid">18167175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Huebers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1756285617734734</fpage>
            <pub-id pub-id-type="pmid">29399045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yanni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alexandru</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mozaffar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A Review of Spasticity Treatments: Pharmacological and Interventional Approaches.</article-title>
            <source>Crit Rev Phys Rehabil Med</source>
            <year>2013</year>
            <volume>25</volume>
            <issue>1-2</issue>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">25750484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malanga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Garay</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Update on tizanidine for muscle spasticity and emerging indications.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>2209</fpage>
            <page-range>2209-15</page-range>
            <pub-id pub-id-type="pmid">18671474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache.</article-title>
            <source>Headache</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-7</page-range>
            <pub-id pub-id-type="pmid">11903539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Chronic daily headache: diagnosis and management.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Apr</month>
            <day>15</day>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>642</fpage>
            <page-range>642-8</page-range>
            <pub-id pub-id-type="pmid">24784123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujieda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia].</article-title>
            <source>No To Hattatsu</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>455</fpage>
            <page-range>455-60</page-range>
            <pub-id pub-id-type="pmid">15560387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Summary of combined clinical analysis of controlled clinical trials with tizanidine.</article-title>
            <source>Neurology</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11 Suppl 9</issue>
            <fpage>S60</fpage>
            <page-range>S60-8; discussion S68-9</page-range>
            <pub-id pub-id-type="pmid">7970013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shakespeare</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Boggild</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Anti-spasticity agents for multiple sclerosis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2001</year>
            <issue>4</issue>
            <fpage>CD001332</fpage>
            <pub-id pub-id-type="pmid">11687107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lataste</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Comparative profile of tizanidine in the management of spasticity.</article-title>
            <source>Neurology</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11 Suppl 9</issue>
            <fpage>S53</fpage>
            <page-range>S53-9</page-range>
            <pub-id pub-id-type="pmid">7970011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groves</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shellenberger</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.</article-title>
            <source>Adv Ther</source>
            <year>1998</year>
            <season>Jul-Aug</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-51</page-range>
            <pub-id pub-id-type="pmid">10186943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>New directions in the treatment of opioid withdrawal.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Jun</month>
            <day>20</day>
            <volume>395</volume>
            <issue>10241</issue>
            <fpage>1938</fpage>
            <page-range>1938-1948</page-range>
            <pub-id pub-id-type="pmid">32563380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society</collab>
              <name>
                <surname>Delgado</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aisen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fehlings</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Shrader</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Tilton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vargus-Adams</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Jan</month>
            <day>26</day>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>336</fpage>
            <page-range>336-43</page-range>
            <pub-id pub-id-type="pmid">20101040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchigami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kakinohana</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hefferan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lukacova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marsala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Platoshyn</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sugahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yaksh</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Marsala</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia.</article-title>
            <source>Neuroscience</source>
            <year>2011</year>
            <month>Oct</month>
            <day>27</day>
            <volume>194</volume>
            <fpage>160</fpage>
            <page-range>160-9</page-range>
            <pub-id pub-id-type="pmid">21871540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagstaff</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bryson</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.</article-title>
            <source>Drugs</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>435</fpage>
            <page-range>435-52</page-range>
            <pub-id pub-id-type="pmid">9074844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coward</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Tizanidine: neuropharmacology and mechanism of action.</article-title>
            <source>Neurology</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11 Suppl 9</issue>
            <fpage>S6</fpage>
            <page-range>S6-10; discussion S10-1</page-range>
            <pub-id pub-id-type="pmid">7970012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tse</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bhuta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of orally administered tizanidine in healthy volunteers.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>1987</year>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>479</fpage>
            <page-range>479-88</page-range>
            <pub-id pub-id-type="pmid">3447935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granfors</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Backman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Laitila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>349</fpage>
            <page-range>349-53</page-range>
            <pub-id pub-id-type="pmid">14998432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su&#x000e1;rez-Lled&#x000f3;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padull&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lozano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cobo-Sacrist&#x000e1;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>J&#x000f3;dar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of Tizanidine Withdrawal Syndrome: A Case Report.</article-title>
            <source>Clin Med Insights Case Rep</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1179547618758022</fpage>
            <pub-id pub-id-type="pmid">29467587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henney</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.</article-title>
            <source>Clin Ther</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>661</fpage>
            <page-range>661-9</page-range>
            <pub-id pub-id-type="pmid">17617289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Ghazawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alzoubi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faidi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-62</page-range>
            <pub-id pub-id-type="pmid">23380428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qureshi</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Ullah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>AlSaleh</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ullah</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Spinal cord injury during the second trimester of pregnancy.</article-title>
            <source>Spinal Cord Ser Cases</source>
            <year>2017</year>
            <volume>3</volume>
            <fpage>17052</fpage>
            <pub-id pub-id-type="pmid">28808585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saper</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lake</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Winner</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.</article-title>
            <source>Headache</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>470</fpage>
            <page-range>470-82</page-range>
            <pub-id pub-id-type="pmid">12167135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Tizanidine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">31643379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bosse</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Retrospective review of Tizanidine (Zanaflex) overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2004</year>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>593</fpage>
            <page-range>593-6</page-range>
            <pub-id pub-id-type="pmid">15462150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaddar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vigneault</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pilote</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patoine</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drolet</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.</article-title>
            <source>J Cardiovasc Pharmacol Ther</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-9</page-range>
            <pub-id pub-id-type="pmid">21317414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitabata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Orita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kamimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiizaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Narukawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akizawa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient.</article-title>
            <source>Ther Apher Dial</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-7</page-range>
            <pub-id pub-id-type="pmid">15828911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishiguro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagishita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A case of drug-induced Stevens-Johnson syndrome-like eruption predominating in mucosa: A case report.</article-title>
            <source>Clin Case Rep</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>1379</fpage>
            <page-range>1379-1381</page-range>
            <pub-id pub-id-type="pmid">32884758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brucculeri</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Potassium wasting nephropathy in the setting of tizanidine overdose: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>250</fpage>
            <pub-id pub-id-type="pmid">33931107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granfors</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Backman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>598</fpage>
            <page-range>598-606</page-range>
            <pub-id pub-id-type="pmid">15592331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudolph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dahmke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kupferschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiler</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>895</fpage>
            <page-range>895-902</page-range>
            <pub-id pub-id-type="pmid">33404754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaugai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Shuey</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>Luther</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>703</fpage>
            <page-range>703-709</page-range>
            <pub-id pub-id-type="pmid">30223305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ikari</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inokuchi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term myocardial toxicity in a patient with tizanidine and etizolam overdose.</article-title>
            <source>J Cardiol Cases</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>78</fpage>
            <page-range>78-81</page-range>
            <pub-id pub-id-type="pmid">30546611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Riehl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bertran</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF<sup>V600</sup> Mutation-Positive Malignancies.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>651</fpage>
            <page-range>651-658</page-range>
            <pub-id pub-id-type="pmid">32311241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meseguer-Henarejos</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Meca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Pina</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Carles-Hern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis.</article-title>
            <source>Eur J Phys Rehabil Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>576</fpage>
            <page-range>576-590</page-range>
            <pub-id pub-id-type="pmid">28901119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hui</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arg&#x000e1;ez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <source>Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2021</year>
            <month>03</month>
            <pub-id pub-id-type="pmid">34260163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgenstern</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vendrell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dan&#x000e9;s</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Liver, Renal, and Cardiovascular Failure After Unintentional Overdose of Tizanidine in a 2-Year-Old Child.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2021</year>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>643</fpage>
            <page-range>643-646</page-range>
            <pub-id pub-id-type="pmid">34421416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>DeMaria</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mauer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Greenwald</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Traube</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Validity of the Richmond Agitation-Sedation Scale (RASS) in critically ill children.</article-title>
            <source>J Intensive Care</source>
            <year>2016</year>
            <volume>4</volume>
            <fpage>65</fpage>
            <pub-id pub-id-type="pmid">27800163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Copley</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>High dose naloxone for acute tizanidine overdose in the emergency department: a case report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>764</fpage>
            <page-range>764-765</page-range>
            <pub-id pub-id-type="pmid">33403870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30226.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmid</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rogan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gl&#x000e4;ssel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Swiss Health Care Professionals' Perspective on the Meaning of Interprofessional Collaboration in Health Care of People with MS-A Focus Group Study.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2021</year>
            <month>Jun</month>
            <day>17</day>
            <volume>18</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">34204475</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
